Proactive Research analyst Emma Ulker says MaxCyte’s () deal with clinical-stage industry leader Allogene Therapeutics () is a clear endorsement of the features of its Flow Electroporation technology.
Described by Allogene as the ‘industry standard’, MXCT’s Flow Electroporation has been chosen to improve yield and efficiency of its lead clinical programmes.
Click here to read Emma Ulker's update on MaxCyte Inc "Allogene deal is validation for new CAR-T wave"
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE